Brief: Irlab Q4 Operating Loss Narrows To SEK 19.4 Million

IRLAB Therapeutics AB

24/02/2021 06:49

Feb 24 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB'S YEAR-END REPORT JANUARY 1 - DECEMBER 31, 2020
    * Q4 OPERATING LOSS SEK 19.4 MILLION VERSUS LOSS SEK 26.3
MILLION
YEAR AGO
    * WITH ACTIVE STUDIES IN BOTH PROJECTS IN CLINICAL PHASE
LATER
THIS YEAR, WE CAN INCREASE INTERNAL RESOURCES ON PRECLINICAL
PROGRAMS P001 AND P003 AS WELL AS REFINE AND STRENGTHEN RESEARCH
PLATFORM ISP
    * GOAL IS TO BECOME EVEN MORE EFFICIENT IN DEVELOPMENT OF
OUR
CLINICAL PROGRAMS AND TO FURTHER INCREASE PRECISION IN DISCOVERY
AND DEVELOPMENT OF DRUG CANDIDATES WITH GOOD SAFETY AND EFFICACY

Source text for Eikon:  ID:nWkr8c4ckX 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))